Ezetimibe
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Ezetimibe |
| DrugBank ID | DB00973 |
| Brand Names (EU) | Ezetimibe |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.86% |
Approved Indication (EMA)
Hypercholesterolaemia and mixed dyslipidaemiaNustendi is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:• in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe • alone in patients who are either statin-intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone,• in
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | homozygous familial hypercholesterolemia | 99.86% | DL |
| 2 | obsolete familial combined hyperlipidemia | 99.68% | DL |
| 3 | hyperlipoproteinemia | 99.63% | DL |
| 4 | familial hypercholesterolemia | 99.38% | DL |
| 5 | hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency | 99.25% | DL |
| 6 | cholesterol-ester transfer protein deficiency | 99.09% | DL |
| 7 | hyperlipidemia, familial combined, LPL related | 98.83% | DL |
| 8 | HIV infectious disease | 98.80% | DL |
| 9 | hypercholesterolemia, autosomal dominant | 98.76% | DL |
| 10 | neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter | 98.69% | DL |
| 11 | hyperlipidemia due to hepatic triglyceride lipase deficiency | 98.57% | DL |
| 12 | familial hyperlipidemia | 98.44% | DL |
| 13 | feline acquired immunodeficiency syndrome | 98.11% | DL |
| 14 | simian immunodeficiency virus infection | 98.11% | DL |
| 15 | hyperlipidemia | 97.34% | DL |
| 16 | hyperalphalipoproteinemia | 97.17% | DL |
| 17 | sitosterolemia | 96.77% | DL |
| 18 | familial chylomicronemia syndrome | 95.51% | DL |
| 19 | hypertriglyceridemia, familial | 94.94% | DL |
| 20 | hypolipoproteinemia (disease) | 93.96% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.